VAT Trap Blog

Because cholesterol is a fat-like substance, it cannot dissolve or travel freely in blood, which is mostly water. To move around, it must be packaged into microscopic transport particles called lipoproteins. One of these, LDL (low-density lipoprotein), acts as the main delivery vehicle, carrying cholesterol from the liver to cells that need it for repair or hormone production. In small amounts, LDL cholesterol is therefore completely normal and necessary. The problem only beg

Cardiometabolic risk develops gradually through visceral fat accumulation, insulin resistance and rising blood pressure. A structured escalation model — from supported self-management to specialist review and selective GLP-1 therapy — allows proportionate intervention before overt cardiovascular disease emerges. Early, coordinated action can alter long-term risk trajectories.

An article by Dr Edward Leatham, Consultant Cardiologist © 2025 E. Leatham This article explores carbohydrates, visceral fat (VAT), and why adding fats to food may lower your cardiometabolic risk. Short on time? Listen to the 15-minute VAT-Trap podcast summary […]

Menopause often brings a hidden shift in fat storage—from hips to abdomen—driven by falling oestrogen and loss of muscle. This article explains why visceral fat matters more than weight, how simple screening can detect risk early, and how HRT, lifestyle change, and modern tools can protect long-term heart and metabolic health.

Ten minutes of strength training, five days a week, is enough to change metabolic health. Like brushing your teeth, it works because it’s sustainable. Keep the time fixed, increase the weights gradually, and focus on strength, not scales. Small daily habits protect muscle, reduce visceral fat, and support long-term health.

When people think about cholesterol, they often imagine it as something floating in the blood, disconnected from body fat. In reality, the type and location of body fat — particularly visceral fat (VAT) — profoundly influence how the liver packages and clears cholesterol. Raised VAT doesn’t just sit silently around the organs; it acts like an endocrine organ, sending chemical distress signals that shift lipid metabolism in an atherogenic direction.

In cardiometabolic medicine, muscle is not a cosmetic tissue but a metabolic organ. Evidence consistently shows that strength, not muscle mass, predicts insulin resistance, cardiovascular risk, and survival. Many older adults are not losing muscle tissue — they are losing muscle function, and that is the pathology that matters.

A 2026 BMJ systematic review confirms that weight regain is the rule after stopping pharmacological weight-management therapy. Across drug classes, most lost weight is regained within 24 months, with parallel loss of metabolic benefit. This reflects biological defence of adiposity, not patient failure.

Medical imaging is the only reliable way to assess true body composition. Weight and smart scales cannot distinguish bone, muscle, or visceral fat. DEXA and low-dose CT provide accurate insight, while home tracking tools support the behavioural change needed to lower visceral fat and long-term cardiometabolic risk.

Smart body composition scales are not metabolic truth machines. Their value lies in engagement, not precision. During weight loss—especially with GLP-1 therapy—hydration and glycogen shifts distort “muscle” readings. Used within a tiered system that prioritises waist, strength, and function, they can support behaviour without undermining progress.

January isn’t just about weight loss. Much winter weight gain occurs as visceral fat, which drives insulin resistance and cardiovascular risk. Measuring your waist, not just your weight, gives a clearer picture of metabolic health. Building muscle and reducing visceral fat supports a healthier metabolism long after January ends.

Coronary heart disease often presents without warning, making early prevention essential. This article outlines a personalised approach to identifying individual risk, detecting underlying coronary inflammation and plaque, and implementing structured preventive strategies. Combining risk scoring, advanced imaging and holistic management, we help patients reduce the likelihood of future heart events.

Reducing saturated fat intake is known to lower “bad” cholesterol (LDL-C) and reduce heart disease risk, but responses vary widely between individuals. Research shows that genetics strongly influence how much LDL rises when people eat foods like butter, cheese, or fatty meats compared with unsaturated fats such as olive oil, nuts, and oily fish. Even on the same diet, LDL responses can differ by up to 1 mmol/L, reflecting genetic differences in intestinal cholesterol absorpti

One of the greatest challenges in the online world is investigator bias. Any “expert” with a strong conviction — whether pro- or anti-statin — can easily find studies that appear to confirm their view. The internet is full of such cherry-picked data. When presented with confident authority, this can sound utterly convincing to a lay audience. The reality is that true medical understanding does not come from one paper, one YouTube video, or one self-proclaimed authority.

Santa’s famous belly is festive, but it highlights an important metabolic lesson: WHERE fat is stored matters more than how it looks. Visceral fat, hidden deep around the organs, drives inflammation and cardiometabolic risk — unlike softer, subcutaneous fat. Understanding this difference is key to real metabolic health.

The most effective path to reducing visceral fat with the help of GLP-1 mimetic is not just to “eat less.” It’s to build more muscle, eat smarter, and track your progress. In this blog, which also forms one of the chapters of an ebook, I outline the programme and tools our patients use in our cardiometabolic clinic.

A coronary stent treats a narrowed artery, not the biology that caused it. Insulin resistance driven by visceral fat promotes inflammation and abnormal healing, increasing restenosis risk. Diabetes is the end stage, but waist size often reveals risk much earlier — making metabolic health central to long-term outcomes after stenting.

GLP-1 drugs seem paradoxical: they enhance insulin action yet shrink dangerous belly fat. The explanation lies in restoring normal insulin timing, reducing chronic insulin exposure, and reversing fat “spillover” from liver to abdomen. Real patient cases show rapid visceral fat loss alongside smoother glucose profiles and lower cardiovascular risk.

The keto and Atkins diets have profound effects on hepatic lipid metabolism, and hence on LDL cholesterol handling. Let’s unpack this carefully through the lens of the endogenous cholesterol pathway.

Epigenetics is the molecular bridge between lifestyle and disease. It explains why two people eating the same meal can have very different glucose spikes, and why decades of stress or sleep loss can push one individual towards metabolic syndrome while another remains resilient.